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2012 el consumo de ATB aumentó un 32% (de 7.4 a 9.8 DHD). El patrón de consumo 
total estuvo dado principalmente por las penicilinas de amplio espectro (53%, 61.1 
DHD), siendo la amoxicilina el ATB más usado (44%, 50,5 DHD). ConClusiones: Las 
medidas regulatorias permitieron disminuir el consumo y los costos/DDD de ATB en 
Chile. Sin embargo, el aumento progresivo observado indica la necesidad de revisar 
la calidad en la utilización de los ATB y el cumplimiento de la regulación vigente.
Muscular-skeletal DisorDers – clinical outcomes studies
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antirheuMatic Drugs: systeMatic review anD Meta-analysis to 
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Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
objeCtives: To evaluate the efficacy and safety of biological disease modifying 
antirheumatic drugs (DMARDs) adalimumab, etanercept, golimumab and infliximab 
in the treatment of psoriatic arthritis (PA) in adults. Methods: We conducted a 
systematic review of controlled clinical trials to access the efficacy and safety of 
these agents in patients with active PsA which have or have not been treated with 
biological DMARDs before. The databases MEDLINE, EMBASE, LILACS and Central 
Cochrane where searched until February 2013 to identify articles that reported data 
on clinical improvement measurements and adverse events. Metanalysis were per-
formed using Review Manager® 5.1 and the Random Effect Model. Results: Seven 
RCTs comparing biological DMARDs with placebo where included; two comparing 
either adalimumabe, etanercept and infliximab to placebo, and one comparing goli-
mumab to placebo. After 12 weeks of treatment, adalimumabe and etanercepte were 
more effective than placebo with respect to 20% improvement from baseline in the 
American College of Rheumatology response criteria (ACR 20); Risk Ratio 3.42 ([2.08, 
5.63]; I² 38%) and 4.15 ([2.71, 6.36]; I² 0%), respectively. After 16 weeks, infliximab 
patients also achieved ACR20 in a greater rate than placebo; RR 5.71 ([3.53, 9.25]; 
I² 0%). However, results after 54 weeks of treatment showed no significant differ-
ences between infliximab and placebo; RR 0.98 ([0.82, 1.18]; I² 0%). Golimumab was 
more effective than placebo at 24 weeks; ACR20 RR 4.53 ([2.75, 7.48]). After 16 weeks 
infliximab shown a 50% reduction in the psoriasis area and severity index (PASI50) 
in a greater rate than placebo, RR 10.67 ([5.52, 20.64]; I² 1%), however, once again 54 
weeks results have shown no significant differences between infliximab and pla-
cebo, RR 0.94 ([0.80, 1.12] I² 66%). Adverse events where similar between the biological 
and placebo groups, nevertheless the placebo group showed a slightly higher rate 
of adverse events than adalimumabe; RR 0.68 ([0.50, 0.92]; I² 0%). ConClusions: 
Results show clinical improvement with the use of biological DMARs in the treat-
ment of PA. Still, there is a lack of evidence to support the spread the use of these 
medicines especially in synthetic DMARD naïve patients.
Muscular-skeletal DisorDers – cost studies
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objeCtives: Rheumatoid arthritis (RA) is a systemic autoimmune disease which 
affects 0.5% of the population in developing countries. In Brazilian public health care 
system (SUS) infliximab, etanercept, adalimumab, golimumab, certolizumab (anti-
TNF), abatacept (T-lymphocyte activation inhibitor) and tocilizumab (IL-6 inhibitor) 
are available as biological treatment. However, only anti-TNF therapies are indicated 
as standard of care for first-line biologic therapy. As tocilizumab is a known effective 
and cost-saving drug for this indication, the present study aims to evaluate the budget 
impact of its inclusion in public RA biologics first-line setting. Methods: A model was 
developed in order to assess the budget impact of tocilizumab reimbursement as a 
first-line biological therapy under SUS perspective from 2014-2018. Only expenditures 
with biologics were accounted according to posology presented in Brazilian Ministry of 
Health RA Guideline considering a mean 67kg-weighted patient. Prices were obtained 
from public disclosures. Forecasts were made pursuant to government sources (IBGE, 
DataSUS) and market research-based data. Different mix scenarios based on vary-
ing growth rate of tocilizumab usage were assessed to evaluate total savings. A two-
way sensitivity analysis was conducted changing diagnosis and biologics use rates. 
Costs were reported in Brazilian currency (BRL1.00~USD0.51 Feb2013). Results: 
Annual costs per patient were BRL20,002, BRL25,625, BRL26,899, BRL18,330, BRL22,386, 
BRL15,232 and BRL27,391, for tocilizumab, etanercept, adalimumab, infliximab, abata-
cept, certolizumab and golimumab, respectively. Concerning different tocilizumab 
public usage scenarios, if it reaches 20% in 2018, savings could sum BRL143,058,554 
(-2.8%) in the analyzed period. Nonetheless by achieving a 40% usage savings 
would be even higher resulting in a potential BRL318,643,978 (-6.3%) economy in 
the same period. Sensitivity analysis showed savings ranges of: BRL101,782,493-
BRL262,029,470 (20% usage scenario) and BRL228,085,067-BRL579,597,311 (40% usage 
scenario). ConClusions: The public inclusion of tocilizumab in 2014 as a RA first-line 
biologic therapy and its usage enhance would result in increasingly savings arousing 
significant impacts in public health care budget.
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objetivos: Avaliar o impacto orçamentário com a incorporação de imunobiológi-
cos endovenosos (IMB-EV) em uma Operadora de Planos de Saúde de Fortaleza 
HPV-associated diseases, medical technologies used in CC, CIN 1, CIN2, CIN3, ASCUS, 
the frequency of their use and the price for the services were determined. Results: 
Vaccination cost for cohort of girls (122,799) resulted in 23.2 million USD. The cost of pre-
vented damage is estimated 16.5 million. Additional cost - 6.7 million. Years of life saved 
- 11172. The coefficient of “cost-effectiveness” of using Cervarix vaccine was calculated 
for 598 USD for one year of life saved. The cost of prevented damage was identified to 
be 38.5 million based on the number of prevented cases of CC, CIN 1, CIN2, CIN3, ASCUS 
and the cost of each case of illness, disability, and death. ConClusions: The cost of 
potential annual preventative damage/gain as a result of Cervarix vaccine application 
may reach 38.5 million USD. When comparing the annual preventative damage to the 
annual cost of vaccination for 12 year old girls in Kazakhstan, the cost of prevention was 
estimated to be 1.7 times more than the cost of one vaccine cohort.
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objetivos: Realizar Análise Custo-Minimização (ACM) do Cloridrato de 
Valganciclovir comparado com Ganciclovir na profilaxia da infecção por CMV em 
transplantados renais. Métodos: Os dados acerca da eficácia semelhante dos anti-
virais foi obtido por meio de Revisão Sistemática. Foram elencadas as seguintes 
categorias de custo direto: medicamento e materiais descartáveis. Foram simulados 
três esquemas de profilaxia: Ganciclovir 1g intravenoso (IV) 3x/dia durante período 
de internação e Ganciclovir 1g VO por 3x/dia até cem dias (Esquema A); Ganciclovir 
1g IV 3x/dia durante internação seguido pelo Valganciclovir 900mg VO uma vez/
dia até cem dias (Esquema B) e Valganciclovir 900mg VO na internação e após a 
alta até completar cem dias de uso (Esquema C). Foram feitos os cálculos relativos 
aos anos de 2010 e 2011 com base no número estimado de pacientes submetidos a 
transplante de um hospital do Sistema Único de Saúde – Brasil. Os valores dos medi-
camentos foram obtidos no Banco de Preços em Saúde (BPS) do DATASUS e a lista 
de conformidade da Câmara de Regulação do Mercado de Medicamentos (CMED) da 
ANVISA. ResultAdos: Em 2010, o custo médio por paciente do esquema A foi de R$ 
18.097,79, do segundo foi de R$ 22.754,63 e do terceiro foi de R$ 21.096,00. Em 2011, 
o custo médio por paciente do primeiro esquema foi de R$ 16.393,27, do segundo 
foi de R$ 22.603,35 e o terceiro foi de R$ 22.346,00. ConClusões: Os resultados 
demonstraram menor custo de profilaxia para CMV com Ganciclovir 1g IV, e o seg-
undo menor com Valganciclovir 900 mg VO. A administração IV do Ganciclovir versus 
a VO do valganciclovir devem ser analisadas com outros estudos, considerando-se 
também os riscos inerentes à administração e reações adversas.
Pin19
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Wiens A., Venson R., Lenzi L., Correr C.J., Pontarolo R.
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objeCtives: To conduct a cost-utility study in the context of Brazil’s Public Health 
Care System of the drugs adefovir, entecavir, interferon alpha, pegylated interferon 
alpha, lamivudine and tenofovir for chronic hepatitis B. Methods: For efficacy and 
safety data, a systematic review was carried out. Utility data and transition probabili-
ties between health states were searched in the literature. The Markov model was 
developed in a time horizon of 40 years with annual cycles for three groups of patients 
with chronic hepatitis B: HBeAg positive, HBeAg negative, and all patients. These strat-
egies were compared to a fourth group that received no treatment. Discount rates of 
5% were applied and sensitivity analyses were performed. Results: Tenofovir offered 
the best cost-utility ratio for the three evaluated models: U$397, U$385 and U$384 (per 
QALY, respectively for HBeAg positive, negative, and all patients). All other strategies 
were completely dominated. The sequence of cost-utility in the three models was: 
tenofovir, entecavir, lamivudine, adefovir, telbivudine, pegylated interferon alpha, and 
interferon alpha. In the sensitivity analysis, adenofovir became less cost-utility than 
telbivudine in some situations. ConClusions: In this study, tenofovir presented the 
best cost-utility ratio. The results obtained in this study will be valuable in decision-
making and in the review of the clinical protocol, mainly involving the allocation of 
available resources for health care.
infection – health care use & Policy studies
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evolución Del consuMo y ventas De antiBióticos en chile 1998-2012
Villagra G., Jirón M.
Universidad de Chile, Santiago, Chile
intRoduCtion: Desde el año 1999 en Chile se exige la receta médica para la venta 
de antibióticos (ATB) en farmacias. Hasta el momento se desconoce el efecto a 
largo plazo de esta medida sobre el consumo y las ventas de ATB. objeCtivos: 
Determinar los niveles y tendencias de consumo y ventas de ATB en Chile antes 
y después de implementar la venta con prescripción médica. MetodologíAs: 
Mediante un estudio retrospectivo de la base de datos del International Marketing 
System (IMS), se analizaron las ventas de ATB en farmacias entre 1998-2012. Las uni-
dades vendidas se transformaron en Dosis Diaria Definidas (DDD), DDD/1000 hab-
itantes/día (DHD) y costo/DDD. Las tendencias se analizaron mediante regresiones 
lineales. ResultAdos: Se observó una disminución del 17% en el consumo de 
ATB con la aplicación de las medidas regulatorias (11.8 a 9.8 DHD, en 1998 y 2012, 
respectivamente). No obstante, las quinolonas, cefalosporinas y macrólidos aumen-
taron un 298%, 31%, 27%, respectivamente, durante el periodo estudiado. La mayor 
disminución respecto al año 1998 ocurrió en el año 2002 (-38%), mientras que entre 
2002 y 2012 hubo un incremento del 34% en el consumo. El costo/DDD disminuyó 
un 15% entre 1998 y 2003 (0.71 a 0.60 USD/DDD), mientras que entre 2003 y 2012 
aumentó en un 47% llegando a 0.88 USD/DDD en 2012. Durante el periodo 2000-
